Peptide COA Guide: Purity, Mass Spec and Red Flags

A peptide COA can be useful, but it is easy to overread. A certificate that says "99% purity" is not the same as an FDA label, a sterility guarantee, a human trial, a dosing protocol or a legal status check.

That distinction matters because many peptides discussed online are not approved medicines. Some are research-only compounds such as BPC-157, CJC-1295, TB-500, PEG-MGF or MOTS-c. Others copy active ingredients from approved GLP-1 products but are sold outside normal drug channels. A COA may answer whether a sample looked like the stated compound under a specific lab method. It cannot turn an unapproved research-market vial into a regulated medication.

Use this guide as a quality-screening framework, not sourcing advice. Injectable or intranasal peptide use should be discussed with qualified clinicians, and approved products should be used according to their label, prescriber and pharmacy instructions. For handling basics, read the peptide reconstitution guide, bacteriostatic water guide, peptide storage guide and how to inject peptides safely.

The Short Version

What A COA Is

COA stands for certificate of analysis. In a regulated manufacturing context, it is part of a larger quality system. In the research-peptide market, it is often a PDF or image used to support a vendor claim.

At minimum, a useful peptide COA should identify:

• The peptide name.
• The batch, lot or sample ID.
• The test date.
• The testing laboratory.
• The method used, such as HPLC, UHPLC, LC-MS or HRMS.
• The result and units.
• The specification or acceptance criterion, if any.
• A chromatogram, spectrum or method detail that supports the result.

If the report is just a cropped screenshot with "99%+" and no batch ID, it is not a strong quality document.

HPLC Purity Is Not The Same As Safety

High-performance liquid chromatography separates compounds in a sample and generates peaks. For peptides, the largest peak may represent the intended peptide, while smaller peaks may represent deletion sequences, truncated peptides, epimers, oxidation products, hydrolysis products or other related impurities.

The common "purity" number is often chromatographic area percent. That means it is a percent of detected peak area under the method used. It does not automatically mean:

• The vial contains the correct amount of peptide.
• The peptide sequence is fully confirmed.
• The vial is sterile.
• Endotoxins are controlled.
• Residual solvents, salts or counterions are acceptable.
• The peptide is stable after shipping or storage.
• The compound has human evidence for the advertised use.

This is why a COA should not be read like a permission slip. It is one quality signal.

Why Mass Spectrometry Matters

Mass spectrometry helps answer a different question: does the molecular mass of the sample match the claimed compound or a related impurity?

That matters because two samples can show a large HPLC peak while still leaving important identity questions. Peptide-drug analytical papers often combine chromatography with high-resolution mass spectrometry to identify and quantify related impurities. Current examples include work on leuprolide, linaclotide, glucagon and semaglutide degradation.

Mass spectrometry is not magic. It depends on sample prep, instrument settings, data interpretation and what the lab was asked to test. A basic mass check is stronger than no identity check, but it still does not establish human use, sterility or medical benefit.

Quantity, Assay And "Filled Amount"

Purity and quantity are different. A vial can test as mostly the right peptide and still contain too little or too much total material. That matters for any drug, and it matters even more for injectable products where concentration and volume drive exposure.

A stronger quality report may include assay, content or net peptide amount. Look for:

• Whether the result is stated in milligrams, micrograms, percent label claim or another clear unit.
• Whether water content or salt form affects the calculation.
• Whether the method distinguishes active peptide from related impurities.
• Whether the report tests a retained sample, a vendor-supplied sample or a market-purchased vial.

For dose-volume math after legitimate reconstitution, use the reconstitution calculator and unit converter. The calculator cannot validate product identity, purity or sterility.

Sterility And Endotoxins Are Separate Tests

Sterility is not implied by HPLC purity. Endotoxins are not implied by mass spectrometry. A report can show a clean chromatographic peak and still say nothing about microbial contamination or bacterial endotoxin.

FDA's compounding materials repeatedly emphasize quality risk, contamination and the fact that compounded drugs are not FDA-approved before marketing. FDA's peptide-specific category 2 page also notes concerns for some nominated peptide substances, including aggregation, peptide-related impurities and active pharmaceutical ingredient characterization.

Those concerns are not abstract. They apply to the exact categories often seen in peptide-market listings: BPC-157, CJC-1295, GHRP-2, GHRP-6, ipamorelin, GHK-Cu injectable products, KPV, PEG-MGF, MOTS-c, Selank, Semax and TB-500 are among the substances FDA has discussed in this risk framework.

Batch Matching Is Non-Negotiable

The report must match the vial. Good signs include:

Even batch matching has limits. A tested sample may not represent every vial if manufacturing, filling, labeling or storage is inconsistent.

Approved, Compounded And Research-Market Peptides

The word "peptide" spans very different product categories.

For an approved medication, the label and pharmacy instructions outrank online COA logic. For a compounded product, FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. For a research-market peptide, a COA is a limited quality signal in a much larger uncertainty stack.

Common Red Flags

Be skeptical when you see:

• "99% pure" with no batch number.
• HPLC only, with no identity test.
• No testing date.
• No named lab.
• No chromatogram or spectrum.
• A COA image reused across multiple vial sizes.
• A report that predates the product batch.
• A mismatch between the product name and the report name.
• Claims that the peptide is for human use when it is not approved for that use.
• "Pharmaceutical grade" without a regulator, label or manufacturer context.
• A vendor saying purity proves sterility.
• A vendor using forum screenshots as evidence.

This applies to popular research compounds and to unapproved GLP-1 copies. Read PeptideStat's compounded GLP-1 guide, retatrutide FDA status guide and Ascension Peptides review for adjacent quality and access context.

What A Stronger COA Packet Looks Like

A stronger packet is more than one number. It may include:

• Batch-specific HPLC or UHPLC purity with chromatogram.
• LC-MS or high-resolution MS identity confirmation.
• Assay or content testing.
• Water content if relevant.
• Residual solvent or counterion information when relevant.
• Sterility and endotoxin testing for products intended for sterile use.
• Clear method names and acceptance criteria.
• Date, lab, analyst or report identifier.
• A lot number that matches the vial and invoice.
• Storage condition and retest or expiration context.

Even then, the conclusion should stay modest. A stronger packet supports a quality claim about the sample tested. It does not establish clinical evidence, dosing, medical appropriateness or legality.

Bottom Line

A peptide COA is useful only if it is batch-specific, method-specific and read with limits. HPLC purity can support a purity claim. Mass spectrometry can support identity. Assay can support content. Sterility and endotoxin tests can support those separate quality questions.

No single COA proves that a research peptide is appropriate for human use. For unapproved injectable peptides, the larger questions remain: regulatory status, clinical evidence, product quality, sterility, storage, route, dose, medical monitoring and adverse-event risk.

References

1. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.

2. FDA. Understanding the Risks of Compounded Drugs.

3. FDA. Bulk Drug Substances Used in Compounding.

4. FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

5. Ramezani M, et al. Development and Validation of a Stability-Indicating RS HPLC Method for Leuprolide Acetate and Its Related Substances.

6. Guo Y, et al. Identification and Quantification of Structurally Related Peptide Impurity in Linaclotide by LC-HRMS.

7. Yu YQ, et al. Absolute Quantitation of Coeluting Impurities in Peptide Drugs Using High Resolution Mass Spectrometry.

8. Rehman A, et al. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS.

9. Figueiredo A, et al. Thermally Stressed Solid-State Stability of Semaglutide.

10. Karongo R, et al. Automated derivatization for enantioselective amino acid analysis of neurotensin synthesized by liquid phase peptide synthesis.